Dexter Pharmaceuticals, a division of Europort by B&S, continues where others stop. It supplies scarce medicines to healthcare professionals whose patients depend on them, enabling the continuation of their treatment plans.
The process
Europort Pharmaceuticals joined the B&S family in 2019. Their extensive customer network and global focus made them a natural partner. While Europort sources and distributes all types of medical supplies, from equipment to OTCs and pharmaceuticals, to the EU, the Middle East, Asia, and Africa, they also supply shortage medicines. By establishing Dexter, they were able to devote an entire business unit to fulfilling the demand for hard-to-obtain medicines.
The close collaboration with Farmanco, an initiative by the KNMP, and the Duch Health Inspection, allows Dexter to monitor shortage medicines and determine suitable substitutes and alternatives. As physicians submit their demands, Dexter takes care of the supply.
By leveraging the extensive Europort network, Dexter is able to source shortage medicines from reliable suppliers in Europe, the United States, Canada, Japan, and Australia. The close relationship with the Dutch Health Inspection allows Dexter to obtain non-registered alternatives and make them available to healthcare providers who need them.